Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai Inc.

WOODCLIFF LAKE, N.J., May, 24, 2016 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Maria Garrigan, as Vice President, Global Regulatory Strategy for the Oncology Business Group (OBG).

In this role, Ms. Garrigan will be responsible for leading the Oncology Regulatory Affairs teams in the United States and United Kingdom. Ms. Garrigan, who joins Eisai with over 20 years of global regulatory experience, will work closely with the company's commercial and OBG strategy organization on the development, planning and management of global regulatory strategies and activities for Eisai's oncology projects. She will provide strategic leadership to the Regulatory Affairs team to ensure the delivery of key objectives.

During her career, Ms. Garrigan has been responsible for the development and implementation of the global regulatory strategies for products in a number of therapeutic areas, including oncology, cardiovascular and gastroenterology. She has led teams in the preparation, coordination and strategy of regulatory submissions to health authorities for the registration and maintenance of new and existing products in the United States and European Union. Ms. Garrigan has also led or supervised meetings with the FDA, as well as planned or participated in meetings with EMA, Health Canada, China's CDE/CFDA and Japan's PMDA.   

"With her vast experience in global regulatory affairs, including nearly a decade focused on oncology, Maria is a very important addition to the Eisai team," said Dr. Alton Kremer, Chief Clinical Officer and Chief Medical Officer, Global Oncology Business Group. "We believe she will play a key role in helping Eisai build its oncology business globally."

Ms. Garrigan joins Eisai from Bayer HealthCare Pharmaceuticals, Inc., where she served as Senior Director, Global Regulatory Affairs, Specialty Medicine, Oncology, since 2013. Her regulatory affairs career began at Berlex, Inc. which was acquired by Bayer in 2006. Ms. Garrigan started her career as a diabetes research scientist at Sandoz, Inc., before joining Berlex, Inc. as a research scientist.

Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and neurology. To learn more about Eisai Inc., please visit us at http://www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey and Pennsylvania, as well as a global demand chain organization that includes facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Eisai Co. Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology. For more information about Eisai Co., Ltd., please visit http://www.eisai.com.

Photo - http://photos.prnewswire.com/prnh/20160523/370949

SOURCE Eisai Inc.